Related Experiment Video
Updated: Aug 4, 2025
06:04
Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024
932
An enduring debate on gliomatosis cerebri
Jiro Akimoto1,2
1Department of Neurosurgery, Kohsei Chuo General Hospital, 1-11-7 Mita, Meguro-Ku, Tokyo, 153-0062, Japan. jiroaki@gmail.com.
Brain Tumor Pathology
|April 6, 2023
Summary
Gliomatosis cerebri (GC) is a glial tumor with a debated classification history. This review discusses its pathological characteristics and argues for its continued clinical relevance.
Area of Science:
- Neuro-oncology
- Pathology
- Molecular Genetics
Background:
- Gliomatosis cerebri (GC) has evolved from a recognized entity to a debated classification within WHO guidelines.
- The 2016 WHO classification removed GC, classifying it as a growth pattern of diffuse glioma, sparking controversy.
Purpose of the Study:
- To review the pathological characteristics of Gliomatosis cerebri.
- To discuss the ongoing debate regarding GC's classification and clinical relevance.
- To advocate for continued research and recognition of GC in Japan.
Main Methods:
- Literature review of GC classification history.
- Discussion of pathological features.
- Author's expert opinion as a neuro-oncologist.
Main Results:
- GC's classification has changed significantly since its initial recognition.
- There is ongoing debate among neuro-oncologists regarding the deletion of GC as a distinct entity.
- The need for multicenter research and molecular pathological evidence for future WHO classifications is highlighted.
Conclusions:
- The classification of Gliomatosis cerebri has been contentious, particularly after the 2016 WHO update.
- Continued research and clinical discussion are essential for understanding and managing GC.
- Developing molecular pathological evidence is crucial for future diagnostic criteria.
